Development of Machine-Learning Algorithms to Predict Attainment of Minimal Clinically Important Difference After Hip Arthroscopy for Femoroacetabular Impingement Yield Fair Performance and Limited Clinical Utility.

PURPOSE

To determine whether machine learning (ML) techniques developed using registry data could predict which patients will achieve minimum clinically important difference (MCID) on the International Hip Outcome Tool 12 (iHOT-12) patient-reported outcome measures (PROMs) after arthroscopic management of femoroacetabular impingement syndrome (FAIS). And secondly to determine which preoperative factors contribute to the predictive power of these models.

METHODS

A retrospective cohort of patients was selected from the UK's Non-Arthroplasty Hip Registry. Inclusion criteria were a diagnosis of FAIS, management via an arthroscopic procedure, and a minimum follow-up of 6 months after index surgery from August 2012 to June 2021. Exclusion criteria were for non-arthroscopic procedures and patients without FAIS. ML models were developed to predict MCID attainment. Model performance was assessed using the area under the receiver operating characteristic curve (AUROC).

RESULTS

In total, 1,917 patients were included. The random forest, logistic regression, neural network, support vector machine, and gradient boosting models had AUROC 0.75 (0.68-0.81), 0.69 (0.63-0.76), 0.69 (0.63-0.76), 0.70 (0.64-0.77), and 0.70 (0.64-0.77), respectively. Demographic factors and disease features did not confer a high predictive performance. Baseline PROM scores alone provided comparable predictive performance to the whole dataset models. Both EuroQoL 5-Dimension 5-Level and iHOT-12 baseline scores and iHOT-12 baseline scores alone provided AUROC of 0.74 (0.68-0.80) and 0.72 (0.65-0.78), respectively, with random forest models.

CONCLUSIONS

ML models were able to predict with fair accuracy attainment of MCID on the iHOT-12 at 6-month postoperative assessment. The most successful models used all patient variables, all baseline PROMs, and baseline iHOT-12 responses. These models are not sufficiently accurate to warrant routine use in the clinic currently.

LEVEL OF EVIDENCE

Level III, retrospective cohort design; prognostic study.